Article Figures & Data
Figures
- FIGURE 1.
Octapeptides, chelators, and radiometals for imaging and targeted radionuclide therapy of neuroendocrine tumors in patients.
- FIGURE 2.
Comparative study (4 h after injection) of 99mTc-HYNIC-TOC vs. 99mTc-HYNIC-TATE in same patient showing high image quality of both tracers and lower liver but higher kidney uptake of 99mTc-HYNIC-TATE. (Courtesy of Alicja Hubalewska-Dydejczyk, Krakow University Hospital.)
- FIGURE 3.
In patient with metastasized NET, planar scintigraphy image 4 h after injection of 111In-DTPA-octreotide (A) and PET image 1 h after injection of 68Ga-DOTATATE (B). Images were obtained 3 wk apart. (Courtesy of Damian Wild, University Hospital Freiburg.)
- FIGURE 4.
68Ga-DOTANOC PET/CT images of patient with multiple secondary NET liver lesions (maximum standardized uptake value, 36) and focal uptake in mesenteric area near duodenum (maximum standardized uptake value, 17). All shown lesions express somatostatin receptor.
- FIGURE 5.
68Ga-DOTANOC PET/CT images (left) and 18F-FDG PET/CT images (right) of patient with pancreatic NET. 68Ga-DOTANOC PET/CT shows increased pancreatic uptake at body and tail level (maximum standardized uptake value, 48), consistent with focal area overexpressing somatostatin receptor. 18F-FDG PET/CT images, in contrast, are negative for uptake.
Tables
- TABLE 1
Peptide Receptors, Disease Indications, and Radiopeptide Probes in Clinical Trials in Europe
Peptide Receptor Disease indication Radiopeptide probe Somatostatin sst2 NETs; gastroenteropancreatic NETs 111In-DTPA-octreotide* 111In-DOTA-landeotide 111In-/90Y-/177Lu-/68Ga-DOTATOC 177Lu-/68Ga-DOTATATE 111In-DOTA-BASS† 99mTc-HYNIC-TOC/-TATE 99mTc-N4-TATE 99mTc-depreotide 18F-deoxyfructosyl-TATE sst2/sst3/sst5 68Ga-DOTANOC Bombesin GRP receptor Prostate cancer, breast cancer 99mTc-RP527 Gastrointestinal stromal tumor 68Ga-BZH3 64Cu-CBC-AR06 68Ga-/177Lu-AMBA Cholecystokinin/gastrin Cholecystokinin 2 Medullary thyroid cancer 111In-DTPA-d-Glu-minigastrin 99mTc-demogastrin 2 RGD peptides αvβ3 integrin Various 18F-galacto-RGD 18F-RGD-K5 18F-AH111585 Substance P Neurokinin 1 Glioblastoma 213Bi-DOTA-substance P 111In-/90Y-DOTAGA-substance P GLP-1/exendin GLP-1 receptor Insulinomas 111In-[Lys40(Ahx-DTPA)NH2]-exendin-4 111In-[Lys40(Ahx-DOTA)NH2]-exendin-4
Jump to section
Related Articles
Cited By...
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- A Half-Century of Nuclear Medicine
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Somatostatin Receptor Antagonists for Imaging and Therapy
- Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy
- Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers
- Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine
- Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
- Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study
- Optimization of RGD-Containing Cyclic Peptides against {alpha}v{beta}3 Integrin
- Radiopeptides for Imaging and Therapy: A Radiant Future
- Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist
- Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer
- Peptide Receptor Radionuclide Therapy in the United States